{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', \"an Investigator might know a subject's identity and have access to his or her genetic data.\", 'Also, regulatory authorities may require access to the relevant files.', 'Administrative Structure', 'The Sponsor of this study is Timber Pharmaceuticals, LLC (Address: 50 Tice Boulevard, Suite', 'A26, Woodcliff Lake, NJ 07677). Study administrative structure including emergency contacts,', 'Clinical Research Organization (CRO), Laboratory, and ancillary services can be found in the', 'Investigator Study Binder.', 'Medical Monitor', 'David A. Amato, DO, FAAD', 'IQVIA Biotech', 'Phone +1 317-626-3143', 'Email: lavid.amato@novellaclinical.com', 'Study Site Initiation', 'The Investigator must not screen any subject prior to completion of the study initiation visit,', 'conducted by CRO. This initiation visit will include a detailed review of the protocol and study', 'procedures.', 'Dissemination of Clinical Study Data', 'The results of the study should be reported within 1 year from the end of the clinical study.', 'Irrespective of the outcome, the Sponsor will submit to the ClinicalTrials.gov database a summary', 'of the results of the clinical study within 1 year from the end of the clinical study. It shall be', 'accompanied by a summary written in a manner that is understandable to laypersons.', 'Data Quality Assurance', 'All subject data relating to the study will be recorded on printed or electronic case report', 'forms (eCRFs) unless transmitted to the Sponsor or designee electronically (eg, laboratory', 'data). The Investigator is responsible for verifying that data entries are accurate and correct', 'by physically or electronically signing the eCRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the eCRF.', 'The Investigator must permit study-related monitoring, audits, IRB/IEC review, and', 'regulatory agency inspections and provide direct access to source data documents.', 'The Sponsor or designee is responsible for the data management of this study including', 'quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that data entered', 'into the eCRF by authorized study center personnel are accurate, complete, and verifiable', '58']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'from source documents; that the safety and rights of subjects are being protected; and that', 'the study is being conducted in accordance with the currently approved protocol and any', 'other study agreements, ICH GCP, and all applicable regulatory requirements.', 'Records and documents, including signed ICFs, pertaining to the conduct of this study must', 'be retained by the Investigator for 15 years after study completion unless local regulations', 'or institutional policies require a longer retention period. No records may be destroyed', 'during the retention period without the written approval of the Sponsor. No records may', 'be transferred to another location or party without written notification to the Sponsor.', 'Source Documents', 'The Investigator/institution should maintain adequate and accurate source documents and study', \"records that include all pertinent observations on each of the study center's subjects. Source data\", 'should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to', 'source data should be traceable, should not obscure the original entry, and should be explained if', 'necessary (eg, via an audit trail).', 'Source documents provide evidence for the existence of the subject and substantiate the', \"integrity of the data collected. Source documents are filed at the Investigator's study center.\", 'Data entered in the eCRF that are transcribed from source documents must be consistent', 'with the source documents or the discrepancies must be explained. The Investigator may', 'need to request previous medical records or transfer records, depending on the study. Also,', 'current medical records must be available.', 'Definition of what constitutes source data can be found in Investigator Study Binder.', 'Study and Study Center Closure', 'The Sponsor designee reserves the right to close the study center or terminate the study at any time', 'for any reason at the sole discretion of the Sponsor. Study centers will be closed upon study', 'completion. A study center is considered closed when all required documents and study supplies', 'have been collected and a study center closure visit has been performed.', 'The Investigator may initiate study center closure at any time, provided there is reasonable cause', 'and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study center by the Sponsor or Investigator may include but are', 'not limited to:', 'Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC', \"or local health authorities, the Sponsor's procedures, or GCP guidelines.\", 'Inadequate recruitment of subjects by the Investigator.', 'Discontinuation of further study treatment development.', '59']\n\n###\n\n", "completion": "END"}